Key result
Prophylactic indobufen cuts 3-year recurrent thrombosis by ~89% versus no treatment.
Why the study?
Does indobufen prevent recurrent thrombosis in patients after an episode of deep venous thrombosis?
RCT (n=123)
Does indobufen prevent recurrent thrombosis in patients after an episode of deep venous thrombosis?
Prophylactic treatment with indobufen significantly reduces the incidence of recurrent deep venous thrombosis over 3 years compared to no treatment.
Indobufen prophylaxis warrants consideration after DVT; confirms benefit in this RCT for secondary prevention.
After an episode of deep venous thrombosis (DVT) 123 patients were randomized into two groups: one was prophylactically treated with indobufen (60 patients), an oral antiplatelet agent, and one had no treatment (63) and acted as a control group. They were followed up for three years and scanned with color duplex scanning (CDS) every three months and any time that signs and symptoms suggested a new episode. In patients receiving indobufen the incidence of thrombosis was 5% in three years while it was significantly higher (46%) in the control group. Also 62% of the new episodes in the control group were asymptomatic (33.3% in the treated group). Results suggest that recurrent DVT is common, often asymptomatic, and confused with sequelae of the initial episode. The prophylaxis with indobufen is an effective measure in preventing recurrent thrombosis and avoiding the progressive deterioration of the deep venous system observed after deep venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Belcaro et al. (1993) conducted an RCT in Deep venous thrombosis (DVT) (n=123). Indobufen vs. No treatment was evaluated on Incidence of recurrent thrombosis. Prophylactic treatment with indobufen significantly reduced the 3-year incidence of recurrent thrombosis compared to no treatment (5% vs 46%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: